The information presented on this website is effective as of
​​​​​​​January 17, 2022.

Canada, EnglishCanada, Français



ResourcesDrug Interactions Finder
PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) is now authorized for use in Canada

PAXLOVID (nirmatrelvir tablets; ritonavir tablets) is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

PAXLOVID is not authorized: 

  • For initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19
  • For pre-exposure or post-exposure prophylaxis for prevention of COVID-19
  • For use longer than 5 consecutive days
Product Monograph Patient Medication Information Health Product Risk Communication  Drug Interactions Finder
PAXLOVID Product Monograph

View the full Product Monograph, which includes dosing, clinical data and safety information.

Click here
PAXLOVID Patient Medication Information

View the full Patient Medication Information, which contains important information for the patient about how to take PAXLOVID and what to expect from treatment.

Click here
PAXLOVID Health Product Risk Communication 

View the Health Product Risk Communication, which includes a description of the health risk associated with PAXLOVID, what health professionals can do and any other important information.

Click here
Next Page Drug Interactions Finder
For more  information

Medical Questions
Call 1-800-463-6001 (Medical Information) or visit pfizermedicalinformation.ca.

General Inquiries
Call our customer service line at 1-888-888-9221 or email us at [email protected].

Reporting a Side Effect

We encourage you to visit our designated safety web portal, where you can efficiently and seamlessly report your experience with PAXLOVID. You can access this web portal at www.pfizersafetyreporting.com

Recipients or their caregivers should contact their healthcare professional if they experience an adverse event after receiving PAXLOVID. Please refer them to the Patient Medication Information. 

Media Requests
Call 1-866-9PFIZER (1-866-973-4937) or email [email protected].​​​​​​​​​​​​​​

This material was developed by Pfizer, as part of the risk minimization plan for PAXLOVID. This material is not intended for promotional use. 

This site is intended only for Canadian healthcare professionals. The products discussed in this site may have different product labelling in different countries. The information provided is for educational purposes only.

Pfizer Logo​​​​​​​Copyright © 2022 Pfizer Inc. All rights reserved. PP-PAX-CAN-0003-EN